EyePoint, Inc. granted stock options to new employees as inducement awards, totaling 158,100 shares, with a ten-year term.
Quiver AI Summary
EyePoint, Inc. announced on May 18, 2026, that it has granted non-statutory stock options to new employees as inducement awards, totaling 158,100 shares of common stock to eight individuals. These options were approved by the Compensation Committee and are aligned with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $12.35 per share and a ten-year term, with a four-year vesting schedule for participants. EyePoint is focused on developing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU™, currently undergoing Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. The company aims to improve patient outcomes while creating value, having treated tens of thousands of patients over the years.
Potential Positives
- EyePoint granted non-statutory stock options to eight new employees, indicating the company's growth and commitment to attracting talent.
- The stock options are tied to the company's performance, aligning employee interests with shareholder value.
- The company is advancing its lead product candidate, DURAVYU™, into Phase 3 pivotal trials, showing progress in its development pipeline.
- Topline data for wet AMD is expected in mid-2026, signaling potential for significant upcoming news regarding the company's product pipeline.
Potential Negatives
- The grant of non-statutory stock options as inducement awards may raise concerns about the company's dependence on stock options for employee motivation, especially if the company's stock performance is unstable.
- The options awarded to new employees are made outside the established Long-Term Incentive Plan, which might suggest a lack of alignment with existing compensation frameworks and could be seen as an irregular approach to employee incentives.
- The company’s lead product candidate, DURAVYU™, is still in Phase 3 trials and has not yet received FDA approval, leaving future revenue streams uncertain and potentially impacting investor confidence.
FAQ
What stock options did EyePoint grant to new employees?
EyePoint granted non-statutory stock options to eight new employees to purchase an aggregate of 158,100 shares of common stock.
When were the stock options granted?
The stock options were granted on May 15, 2026.
What is the exercise price of the granted stock options?
The exercise price of the stock options is $12.35 per share, which was the closing price on the grant date.
How long do the stock options last?
The stock options have a ten-year term and vest over four years.
What is EyePoint's main focus?
EyePoint is focused on developing innovative therapeutics for serious retinal diseases, particularly with its lead product candidate DURAVYU™.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EYPT Insider Trading Activity
$EYPT insiders have traded $EYPT stock on the open market 9 times in the past 6 months. Of those trades, 1 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $EYPT stock by insiders over the last 6 months:
- ASSET MANAGEMENT, LP CORMORANT sold 60,000 shares for an estimated $942,240
- RAMIRO RIBEIRO (Chief Medical Officer) has made 0 purchases and 4 sales selling 49,856 shares for an estimated $844,001.
- NANCY LURKER has made 0 purchases and 3 sales selling 10,000 shares for an estimated $150,942.
- JAY S. DUKER (President and CEO) purchased 1,500 shares for an estimated $19,723
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$EYPT Hedge Fund Activity
We have seen 119 institutional investors add shares of $EYPT stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TCG CROSSOVER MANAGEMENT, LLC removed 3,572,335 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $46,047,398
- COMMODORE CAPITAL LP added 2,825,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $36,414,250
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,259,782 shares (-40.6%) from their portfolio in Q1 2026, for an estimated $29,128,589
- CITADEL ADVISORS LLC added 1,905,875 shares (+inf%) to their portfolio in Q1 2026, for an estimated $24,566,728
- ORBIMED ADVISORS LLC removed 1,399,167 shares (-56.7%) from their portfolio in Q1 2026, for an estimated $18,035,262
- EVENTIDE ASSET MANAGEMENT, LLC added 1,245,583 shares (+inf%) to their portfolio in Q1 2026, for an estimated $16,055,564
- VANGUARD GROUP INC added 1,027,623 shares (+27.1%) to their portfolio in Q4 2025, for an estimated $18,774,672
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$EYPT Price Targets
Multiple analysts have issued price targets for $EYPT recently. We have seen 4 analysts offer price targets for $EYPT in the last 6 months, with a median target of $32.5.
Here are some recent targets:
- Lisa Walter from RBC Capital set a target price of $37.0 on 05/07/2026
- Yigal Nochomovitz from Citigroup set a target price of $35.0 on 03/09/2026
- Yi Chen from HC Wainwright & Co. set a target price of $30.0 on 03/05/2026
- Daniil Gataulin from Chardan Capital set a target price of $29.0 on 03/04/2026
Full Release
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 158,100 shares of EyePoint common stock to eight new employees. The stock options were granted on May 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $12.35 per share, the closing price of EyePoint’s common stock on May 15, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU ™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
[email protected]
/
[email protected]
Media:
Helen O’Gorman
FTI Consulting
[email protected]
